Hillstream BioPharma announced that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange. "Ever since our IPO, our Nasdaq listing is an important underlying component of our capital markets strategy," said Randy Milby, CEO of Hillstream. "Although we don’t control our share price, we remain ever steadfast and working as diligently as possible to advance our therapeutic candidates and execute on our business plan."
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HILS:
- Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
- Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
- Hillstream BioPharma signs exclusive option agreement with ABSI
- Hillstream Soars on Promising HSB-1216 Data in Lung Cancer